<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820520</url>
  </required_header>
  <id_info>
    <org_study_id>RE11-09</org_study_id>
    <nct_id>NCT01820520</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery</brief_title>
  <official_title>Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study designed to evaluate the safety and efficacy of double staining with brilliant blue G
      0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or
      epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography,
      pattern reversal electroretinogram and multifocal electroretinogram.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomography</measure>
    <time_frame>6 months</time_frame>
    <description>Average thickness of ganglion cell layer - inner plexiform layer measured by spectral domain optical coherence tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amplitude of pattern reversal electroretinogram</measure>
    <time_frame>6 months</time_frame>
    <description>Amplitude of pattern reversal electroretinogram (in microvolts)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amplitude of b-wave of multifocal electroretinogram</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of the amplitude of the b-wave of multifocal electroretinogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Visual acuity measured with an Early Treatment Diabetic Retinopathy Study chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6 months</time_frame>
    <description>Presence of any ocular complication</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Macular Hole</condition>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Double staining with brilliant blue G during vitrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brilliant blue G</intervention_name>
    <description>Double staining with brilliant blue G 0.025% for macular surgery</description>
    <arm_group_label>Double staining with brilliant blue G during vitrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 18 years of older

          -  Signing of informed consent

          -  Macular pathology requiring vitrectomy (epiretinal membrane, macular hole,
             vitreomacular traction syndrome)

        Exclusion Criteria:

          -  Diagnosis of glaucoma

          -  Known allergy to brilliant blue G
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hugo Sepúlveda-Vázquez, MD</last_name>
    <phone>+52(55)10841400</phone>
    <phone_ext>1172</phone_ext>
    <email>hugo_dr14@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerardo Garcia-Aguirre, MD</last_name>
    <phone>+52(55)10841400</phone>
    <phone_ext>1172</phone_ext>
    <email>jerry_gar@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonieta Burgoa</last_name>
      <phone>+52(55)10841400</phone>
      <phone_ext>1172</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Hugo Sepúlveda-Vázquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asociación para Evitar la Ceguera en México</investigator_affiliation>
    <investigator_full_name>Hugo Sepúlveda-Vázquez</investigator_full_name>
    <investigator_title>Retina Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

